Multiplexed MRM-based quantitation of candidate cancer biomarker proteins in undepleted and non-enriched human plasma

Proteomics

Volumn 13, Issue 14, 2013, Pages 2202-2215

  Percy, Andrew J ^a   Chambers, Andrew G ^a   Yang, Juncong ^a   Borchers, Christoph H ^a,b  

^a UNIVERSITY OF VICTORIA   (Canada)

^b UNIVERSITY OF VICTORIA   (Canada)

Author keywords

Biomedicine; Cancer biomarkers; MRM; MS; Plasma; Quantitative analysis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 13A; FOLLISTATIN; INTERCELLULAR ADHESION MOLECULE 1; KININOGEN; SCATTER FACTOR; SOMATOMEDIN BINDING PROTEIN 1; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; AMIDATION; ANTIBODY AFFINITY; ARTICLE; ASSAY; BREAST CANCER; CANCER DIAGNOSIS; CANCER PROGNOSIS; CONCENTRATION (PARAMETERS); DEAMINATION; DIAGNOSTIC ACCURACY; DISSOCIATION; DISULFIDE BOND; FEMALE; HUMAN; HUMAN TISSUE; MALE; MULTIPLEXED MULTIPLE REACTION MONITORING ASSAY; PLASMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUANTITATIVE ANALYSIS;

BIOMEDICINE; CANCER BIOMARKERS; MRM; MS; PLASMA; QUANTITATIVE ANALYSIS;

ADOLESCENT; ADULT; BLOOD PROTEINS; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTEOME; PROTEOMICS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84879974563     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201200316     Document Type: Article

References (69)

1. Jemal, A., Bray, F., Center, M. M., Ferlay, J. et al., Global cancer statistics. Cancer J. Clin. 2011, 61, 69-90.
2. Anderson, N. L., Anderson, N. G., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Prot. 2002, 1, 845-867.
3. Zhang, H., Liu, A. Y., Loriaux, P., Wollscheid, B. et al., Mass spectrometric detection of tissue proteins in plasma. Mol. Cell Prot. 2007, 6, 64-71.
4. Keshishian, H., Addona, T., Burgess, M., Kuhn, E., Carr, S. A., Quantitative, multiplexed assays for low abundance proteins in plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell Prot. 2007, 6, 2212-2229.
5. Keshishian, H., Addona, T., Burgess, M., Mani, D. R. et al., Quantification of cardiovascular biomarkers in patient plasma by targeted mass spectrometry and stable isotope dilution. Mol. Cell Prot. 2009, 8, 2339-2349.
6. Anderson, L., Hunter, C. L., Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell Prot. 2006, 5, 573-588.
7. Parker, C. E., Pearson, T. W., Anderson, N. L., Borchers, C. H., Mass-spectrometry-based clinical proteomics - a review and prospective. Analyst 2010, 135, 1830-1838.
8. Hüttenhain, R., Soste, M., Selevsek, N., Röst, H. et al., Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci. Trans. Med. 2012, 4, 142ra94.
9. Polaskova, V., Kapur, A., Khan, A., M. P., M., Baker, M. S., High-abundance protein depletion: comparison of methods for human plasma biomarker discovery. Electrophoresis 2010, 31, 471-482.
10. Kim, K., Yu, J., Min, H., Kim, H. et al., Online monitoring of immunoaffinity-based depletion of high-abundance blood proteins by UV spectrophotometry using enhanced green fluorescence protein and FITC-labeled human serum albumin. Proteome Sci. 2010, 8, 62.
11. Domanski, D., Percy, A. J., Yang, J., Chambers, A. G. et al., MRM-based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma. Proteomics 2012, 12, 1222-1243.
12. Chen, Y.-T., Chen, H.-W., Domanski, D., Smith, D. S. et al., Multiplexed quantification of 63 proteins in human urine by multiple reaction monitoring-based mass spectrometry for discovery of potential bladder cancer biomarkers. J. Prot. 2012, 75, 3529-3545.
13. Kuzyk, M. A., Smith, D., Yang, J., Cross, T. J. et al., Multiple reaction monitoring-based, multiplexed, absolute quantitation of 45 proteins in human plasma. Mol. Cell Prot. 2009, 8, 1860-1877.
14. Anderson, L., Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J. Physiol. 2005, 563, 23-60.
15. Liao, H., Wu, J., Kuhn, E., Chin, W. et al., Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum. 2004, 50, 3792-3803.
16. Percy, A. J., Chambers, A. G., Yang, J., Domanski, D., Borchers, C. H., Comparison of standard-flow and nano-flow liquid chromatography systems for MRM-based quantitation of putative plasma biomarker proteins. Anal. Bioanal. Chem. 2012, 404, 1089-1101.
17. Polanski, M., Anderson, N. L., A list of candidate cancer biomarkers for targeted proteomics. Biomarker Insights 2006, 1, 1-48.
18. Addona, T. A., Shi, X., Keshishian, H., Mani, D. R. et al., A pipeline that integrates the discovery and verification of plasma protein biomarkers reveals candidate markers for cardiovascular disease. Nat. Biotech. 2011, 29, 635-643.
19. Neagu, M., Constantin, C., Tanase, C., Boda, D., Patented biomarker panels in early detection of cancer. Recent Patents Biomarkers 2011, 1, 10-24.
20. Domanski, D., Cohen Freue, G., Sojo, L., Kuzyk, M. A. et al., The use of multiplexed MRM for the discovery of biomarkers to differentiate iron-deficiency anemia from anemia of inflammation. J. Prot. 2011, 75, 3514-3528.
21. Kadowaki, M., Sangai, T., Nagashima, T., Sakakibara, M. et al., Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach. J. Cancer Res. Clin. Oncol. 2011, 137, 1105-1115.
22. Cho, W., Jung, K., Regnier, F. E., Use of glycan targeting antibodies to identify cancer-associated glycoproteins in plasma of breast cancer patients. Anal. Chem. 2008, 80, 5286-5292.
23. Rasheed, Z., Ahmad, R., Ali, R., Structure and immunological function of oxidised albumin in lung cancer: its potential role as a biomarker of elevated oxidative stress. Br. J. Biomed. Sci. 2009, 66, 67-73.
24. Clarke, C. H., Yip, C., Badgwell, D., Fung, E. T. et al., Proteomic biomarkers apolipoprotein A1, truncated transthyretin and connective tissue activating protein III enhance the sensitivity of CA125 for detecting early stage epithelial ovarian cancer. Gynecol. Oncol. 2011, 122, 548-553.
25. Liu, L., Liu, J., Dai, S., Wang, X. et al., Reduced transthyretin expression in sera of lung cancer. Cancer Sci. 2007, 98, 1617-1624.
26. Artac, M., Altundag, K., Leptin and breast cancer: an overview. Med. Oncol. 2012, 29, 1510-1514.
27. Yasui, W., Oue, N., Ito, R., Kuraoka, K., Nakayama, H., Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci. 2004, 95, 385-392.
28. Yamamoto-Ishikawa, K., Suzuki, H., Nezu, M., Kamiya, N. et al., The isolation and identification of apolipoprotein C-I in hormone-refractory prostate cancer using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Asian J. Androl. 2009, 11, 299-307.
29. López-Árias, E., Aguilar-Lemarroy, A., Felipe Jave-Suárez, L., Morgan-Villela, G. et al., Alpha 1-antitrypsin: a novel tumor-associated antigen identified in patients with early-stage breast cancer. Electrophoresis 2012, 33, 2130-2137.
30. Xu, Y., Zhang, J., Han, J., Pan, X. et al., Curcumin inhibits tumor proliferation induced by neutrophil elastase through the upregulation of α1-antitrypsin in lung cancer. Mol. Oncol. 2012, 6, 405-417.
31. Cohen, M., Yossef, R., Erez, T., Kugel, A. et al., Apolipoproteins C-I and C-III are reduced in stomach cancer patients: results from MALDI-based peptidome and immuno-based clinical assays. PLoS One 2011, 6, e14540.
32. Park, K. S., Kim, H., Kim, N. G., Cho, S. Y. et al., Proteomic analysis and molecular characterization of tissue ferritin light chain in hepatocellular carcinoma. Hepatology 2002, 35, 1459-1466.
33. Jézéquel, P., Campion, L., Spyratos, F., Loussouarn, D. et al., Validation of tumor-associated macrophage ferritin light chain as a prognostic biomarker in node-negative breast cancer tumors: a multicentric 2004 national PHRC study. Int. J. Cancer 2012, 131, 426-437.
34. Akcay, M. N., Yilmaz, I., Polat, M. F., Akcay, G., Serum paraoxonase levels in gastric cancer. Hepatogastroenterology 2003, 50, cclxxiii-cclxxv.
35. Akcay, M. N., Polat, M. F., Yilmaz, I., Akcay, G., Serum paraoxonase levels in pancreatic cancer. Hepatogastroenterology 2003, 50, ccxxv-ccxxvii.
36. Kuzyk, M. A., Parker, C. E., Borchers, C. H., Development of MRM-based assays for plasma proteins in: Backvall, H. (Eds.), Methods in Molecular Biology. Humana Press, Totowa, NJ, USA 2013.
37. Tabb, D. L., Huang, Y., Wysocki, V. H., Yates, J. R., Influence of basic residue content on fragment ion peak intensities in low-energy collision-induced dissociation spectra of peptides. Anal. Chem. 2004, 76, 1243-1248.
38. Abbatiello, S. E., Mani, D. R., Keshishian, H., Carr, S. A., Automated detection of inaccurate and imprecise transitions in peptide quantification by multiple reaction monitoring mass spectrometry. Clin. Chem. 2010, 56, 291-305.
39. Sherman, J., McKay, M. J., Ashman, K., Molloy, M. P., How specific is my SRM?: the issue of precursor and product ion redundancy. Proteomics 2009, 9, 1120-1123.
40. Keil, B., Specificity of Proteolysis, Springer-Verlag, Heidelberg 1992.
41. Schlosser, A., Pipkorn, R., Bossemeyer, D., Lehmann, W., Analysis of protein phosphorylation by a combination of elastase digestion and neutral loss tandem mass spectrometry. Anal. Chem. 2001, 73, 170-176.
42. Molina, H., Horn, D. M., Tang, N., Mathivanan, S., Pandey, A., Global proteomic profiling of phosphopeptides using electron transfer dissociation tandem mass spectrometry. Proc. Natl. Acad. Sci. USA 2007, 104, 2199-2204.
43. Cieśla, J., Fra{ogonek}czyk, T., Rode, W., Phosphorylation of basic amino acid residues in proteins: important but easily missed. Acta Biochimica Polonica 2011, 58, 137-148.
44. Rodriguez, J., Gupta, N., Smith, R. D., Pevzner, P. A., Does trypsin cut before proline? J. Prot. Res. 2008, 7, 300-305.
45. US Department of Health and Human Services, Food and drug administration. Guidance for Industry Bioanalytical Method Validation, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070107.pdf 2001.
46. Anderson, N. L., The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin. Chem. 2010, 56, 177-185.
47. US Food and Drug Administration. Draft guidance for industry: bioanalytical method validation. US Food and Drug Administration, Rockville, MD, USA 1999.
48. Sumner, L. W., Amberg, A., Barrett, D., Beger, R. et al., Proposed minimum reporting standards for chemical analysis. Metabolomics 2007, 3, 211-221.
49. Proc, J. L., Kuzyk, M. A., Hardie, D. B., Yang, J. et al., A quantitative study of the effects of chaotropic agents, surfactants, and solvents on the digestion efficiency of human plasma proteins by trypsin. J. Prot. Res. 2010, 9, 5422-5437.
50. Glatter, T., Ludwig, C., Ahrné, E., Aebersold, R. et al., Large-scale quantitative assessment of different in-solution protein digestion protocols reveals superior cleavage efficiency of tandem LysC/trypsin proteolysis over trypsin digestion. J. Prot. Res. 2012, 11, 5145-5156.
51. Whiteaker, J. R., Zhao, L., Anderson, L., Paulovich, A. G., An automated and multiplexed method for high throughput peptide immunoaffinity enrichment and multiple reaction monitoring mass spectrometry-based quantification of protein biomarkers. Mol. Cell Prot. 2010, 9, 184-196.
52. Aguilar-Mahecha, A., Kuzyk, M. A., Domanski, D., Borchers, C. H., Basik, M., Comparison of blood collection tubes and processing protocols for plasma proteomics studies. Plos One 2012, 7, e38290.
53. Fusaro, V. A., Mani, D. R., Mesirov, J. P., Carr, S. A., Prediction of high-responding peptides for targeted protein assays by mass spectrometry. Nat. Biotech. 2009, 27, 190-198.
54. Jaquinod, M., Trauchessec, M., Huillet, C., Louwagie, M. et al., Mass spectrometry-based absolute protein quantification: PSAQ™ strategy makes use of "noncanonical" proteotypic peptides. Proteomics 2012, 12, 1217-1221.
55. Brun, V., Dupuis, A., Adrait, A., Marcellin, M. et al., Isotope-labeled protein standards: toward absolute quantitative proteomics. Mol. Cell Prot. 2007, 6, 2139-2149.
56. Lebert, D., Dupuis, A., Garin, J., Bruley, C., Brun, V., Production and use of stable isotope-labeled proteins for absolute quantitative proteomics. Meth. Mol. Biol. 2011, 753, 93-115.
57. Hoofnagle, A. N., Becker, J. O., Oda, M. N., Cavigiolio, G. et al., Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. Clin. Chem. 2012, 58, 777-778.
58. Kuhn, E., Whiteaker, J. R., Mani, D. R., Jackson, A. M. et al., Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol. Cell Prot. 2012, 11, M111.013854.
59. Singh, R., Crow, F. W., Babic, N., Lutz, W. H. et al., A liquid chromatography-mass spectrometry method for the quantification of urinary albumin using a novel 15N-isotopically labeled albumin internal standard. Clin. Chem. 2007, 53, 540-542.
60. Agger, S. A., Marney, L. C., Hoofnagle, A. N., Simultaneous quantification of apolipoprotein a-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry. Clin. Chem. 2010, 56, 1804-1813.
61. Duncan, M. W., Yergey, A. L., Patterson, S. D., Quantifying proteins by mass spectrometry: the selectivity of SRM is only part of the problem. Proteomics 2009, 9, 1124-1127.
62. Gilar, M., Olivova, P., Daly, A. E., Gebler, J. C., Two-dimensional separation of peptides using RP-RP-HPLC system with different pH in first and second separation dimensions. J. Sep. Sci. 2005, 28, 1694-1703.
63. Shi, T., Fillmore, T. L., Sun, X., Zhao, R. et al., Antibody-free, targeted mass-spectrometric approach for quantification of proteins at low picogram per milliliter levels in human plasma/serum. Proc. Natl. Acad. Sci. USA 2012, 109, 15395-15400.
64. Polanski, M., Anderson, N. L., A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights 2007, 1, 1-48.
65. Dieplinger, H., Ankerst, D. P., Burges, A., Lenhard, M. et al., Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2009, 18, 1127-1133.
66. Levo, Y., Wollner, S., Treves, A. J., Serum amyloid P-component levels in patients with malignancy. Scandavian J. Immunol. 1986, 24, 147-151.
67. Hortin, G. L., Sviridov, D., Anderson, N. L., High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin. Chem. 2008, 54, 1608-1616.
68. Reddigari, S. R., Kuna, P., Miragliotta, G., Shibayama, Y. et al., Human high molecular weight kininogen binds to human umbilical vein endothelial cells via its heavy and light chains. Blood 1993, 81, 1306-1311.
69. Esmat, S. M., El-Sherif, H. E., Anwar, S., Abdel-Atty, S., Abdel-Reheim, H. A., Serum amyloid a protein level, and its significance in systemic lupus erythematosus patients. Egyptian Dermatol. Online J. 2005, 1, 1-12.